Atomera is a highly speculative semiconductor-IP call option: technical milestones expand its upside, but pre-revenue economics, dilution, and commercialization delays dominate the near-term risk/reward.
Overview
Atomera is a development-stage semiconductor materials and IP licensing company commercializing MST, a patented oxygen-monolayer technology designed to improve silicon transistor performance by up to a full technology node. Its staged revenue model begins with engineering, wafer, and MSTcad fees and culminates in recurring HVM royalties. **The technical opportunity is broad:** the company targets GAA logic, DRAM, 3D NAND, power, and RF markets within a $600 billion-$750 billion semiconductor industry, with NAND periphery potentially more than doubling its wafer TAM and GaN-on-silicon addressing 5G/6G RF. Q2 2026 revenue rose to $158,000 from $11,000 in Q1, but remained immaterial against $6.9 million of GAAP operating expenses; the GAAP loss widened to $6.336 million and adjusted EBITDA loss to $5.0 million. Cash was $38.4 million, supported by first-half equity raises, while 2026 non-GAAP operating-expense guidance increased to approximately $18.75 million. **Valuation is highly binary:** trailing EV/Sales exceeds 540x and traditional multiples are not meaningful. The principal near-term catalyst is an HVM license or PDK integration following the GAA milestone; the five-year probability-weighted target is $13.30 versus a $4.11 baseline.